Clarifies that product approval from U.S. Food and Drug Administration is not required for drug manufacturer to file registration statement, and specifies timeframe by which DOH must review registration statements.
Bill status
signed
all 5 stages cleared
Introduction
Apr 2016
Committee Review
Oct 2016
Senate Passage
Jun 2016
General Assembly Passage
Oct 2016
Signed into Law
Dec 2016
Introduced Apr 18, 2016
Signed Dec 5, 2016
Floor votes
How they voted
This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history
Actions timeline
Total actions
8
Key actions
5
Committee
3
Dec 5, 2016
Signed into law
Approved P.L.2016, c.73.
executive
Oct 20, 2016
Legislature · Passed
Passed Assembly (Passed Both Houses) (73-0-0)
legislature
Oct 6, 2016
Legislature · Passed
Reported out of Assembly Committee, 2nd Reading
legislature
Jun 30, 2016
Committee
Received in the Assembly, Referred to Assembly Health and Senior Services Committee
legislature
Jun 30, 2016
Legislature · Passed
Passed Senate (40-0)
legislature
May 16, 2016
Legislature · Passed
Reported out of Senate Committee, 2nd Reading
legislature
Apr 18, 2016
Introduced
Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
legislature
0 primary · 0 co-sponsors
Sponsors
No sponsor information available.
Ask Maddy
·
AI policy assistant
Ask Maddy about S 2024
Scope: NJ
Hi! I can help you understand S 2024. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline